My Track Record + How I Invest (Free 90 Day Trial Offer Inside)None – ATTO
Pitch Summary: ATTO represents a cautionary tale of a highly leveraged turnaround investment gone wrong. Initially, the company showed promise with its turnaround strategy, but a series of adverse events, including a cyber-attack and currency hedging issues, severely impacted its operations. The management’s poor handling of these crises, coupled with the investor’s decision to double […]
My Track Record + How I Invest (Free 90 Day Trial Offer Inside)None – QLTU.TA
Pitch Summary: QLTU has been an exceptional investment, discovered through a bespoke screening process. The company’s rapid growth and under-the-radar status contributed to its initial undervaluation. Despite being listed on a less prominent exchange, QLTU demonstrated strong value and quality attributes, including robust earnings, a solid balance sheet, and effective management with significant insider ownership. […]
My Track Record + How I Invest (Free 90 Day Trial Offer Inside)None – CEE
Pitch Summary: CEE is a strategic investment in the potential resolution of the Ukraine/Russia conflict. The fund currently trades at a premium over its Eastern European assets, excluding its Russian holdings, which are valued at zero due to sanctions. These Russian assets, once the largest part of the portfolio, are still owned by the fund […]
I am ending micro-coverage of Village Super Market, and currently favor a peerNatural Grocers by Vitamin Cottage – NGVC
Pitch Summary: Natural Grocers by Vitamin Cottage presents an attractive investment opportunity, trading at approximately 12x scalpavelli-adjusted trailing earnings. The company is well-managed and focuses on health-oriented products, differentiating it from competitors. An 8% earnings yield combined with a potential 4% to 5% long-term earnings per share growth could offer a compelling long-term return. The […]
I am ending micro-coverage of Village Super Market, and currently favor a peerVillage Super Market – VLGEA
Pitch Summary: Village Super Market is currently trading at approximately 9.5x scalpavelli-adjusted trailing earnings with a 33% net cash position and a 10% working capital deficit. Despite the chaotic price action, the company’s strong balance sheet and modest growth potential from a sub-10x earnings base level make it a value trap that is comfortable to […]
CLOSED: $VLN.TO: Clean-up and take-outVelan Inc. – VLN.TO
Pitch Summary: Velan Inc. has executed a significant strategic shift by selling its French subsidiary, which clears a major obstacle for a potential acquisition. The sale of Velan France to Framatome for $198.4M USD, along with the settlement of asbestos liabilities, positions the company for a potential take-out. The company’s operational improvements, including a record […]
Onity Group (NYSE: ONIT)Onity Group – ONIT
Pitch Summary: Onity Group, previously Ocwen Financial, has undergone a significant transformation from a troubled company burdened with lawsuits and high leverage to a structurally profitable entity with a healthier balance sheet. The company has resolved its past issues, integrated solid operational systems from its acquisition of PHH Corporation, and is now focused on traditional […]
CLOSED: Neo Performance Materials (TSX: NEO)Neo Performance Materials – NEO.TO
Pitch Summary: Neo Performance Materials presents a compelling investment opportunity due to its strategic position in the rare earths industry, particularly in the downstream processing of neodymium magnets. The company is trading at a low multiple with a net cash balance sheet and a 5% dividend yield. It has recently improved its management team and […]
From searching to being found: U.C.A. AG investment Pflegia smart way out of the personnel shortage. $UCA1U.C.A. Aktiengesellschaft – UCA.DE
Pitch Summary: U.C.A. AG has demonstrated a successful investment strategy with its subsidiary Pflegia, which has revolutionized the recruitment process in the nursing sector through a reverse recruiting model. This approach has led to significant growth, with Pflegia becoming a dominant player in the German care industry. U.C.A.’s expansion of this model to the skilled […]
A timely post! Bombardier – Leading Private Jet Vendor in a Duopoly caught in a Tariff StormBombardier Inc. – BBD-B.TO
Pitch Summary: Bombardier Inc. has refocused its business on the private jet market after divesting its train and commercial aircraft segments. The company has shown a steady increase in jet deliveries, particularly in the medium and large cabin segments, and has improved its financial position by reducing debt. With a strong market position and a […]
Dollarama – 1 year laterDollarama Inc. – DOL.TO
Pitch Summary: Dollarama has shown strong financial performance with a 28% increase in EPS and an 8.2% rise in sales. The company has a dominant market share in Canada and is expanding internationally through Dollarcity and the acquisition of The Reject Shop in Australia. These expansions are expected to drive future growth and operational synergies. […]
Alphabet Inc – when a monopoly gets inefficient. Google – GOOGL
Pitch Summary: Google’s dominant position in search and advertising is well-known, but its operational efficiency is currently under scrutiny. The company faces rising costs to maintain its competitive moat, leading to a lower NabzdykRatings moat score. Despite these challenges, Google continues to generate significant cash flow, and its diverse business segments, including YouTube and Google […]
FDA Clears Oral Wegovy: Update on Novo Nordisk and WeightWatchersWeightWatchers – WW
Pitch Summary: WeightWatchers is positioned to benefit significantly from the FDA approval of oral Wegovy, as it could become the operating system connecting the drug to millions of patients. The company’s platform is anticipated to compound 100× over the long term if oral GLP-1s scale effectively. With the approval, WeightWatchers can activate during the crucial […]
FDA Clears Oral Wegovy: Update on Novo Nordisk and WeightWatchersNovo Nordisk – NVO
Pitch Summary: Novo Nordisk has received FDA approval for oral Wegovy, marking a significant milestone as the first oral GLP-1 treatment for the US obesity market. This approval positions Wegovy as a chronic disease therapy, not just a cosmetic weight-loss product, with an on-label claim for reducing cardiovascular risks. The company is prepared for a […]
FDA vs. HIMS: Why the Oral “Wegovy Copy” Crackdown Changes the GLP-1 GameNovo Nordisk – NVO
Pitch Summary: Novo Nordisk recently faced a significant stock price drop following disappointing 2026 guidance and competitive threats from HIMS’s launch of a cheaper compounded semaglutide pill. However, the FDA’s decisive intervention to restrict GLP-1 APIs for non-approved compounded drugs strengthens Novo’s market position. The FDA’s actions protect Novo’s intellectual property and market share by […]
12x FCF for a Future Multi-Bagger? Meet Uber Technologies!Uber Technologies, Inc. – UBER
Pitch Summary: Uber is positioned as a long-term investment opportunity due to its combination of scale, re-accelerating growth, expanding profitability, and strong cash flows. Despite recent stock performance, Uber’s fundamentals are strong, with significant growth in monthly active users, revenue, and gross bookings. The company’s asset-light model and global reach provide a competitive advantage, and […]
SAP – One of Europe’s Best Businesses is on SaleSAP SE – SAP.DE
Pitch Summary: SAP SE is a resilient and deeply embedded enterprise software provider, crucial for the operations of the world’s largest companies. Despite recent stock price declines, SAP’s transition to cloud services is expanding its total addressable market and revenue potential. The company has demonstrated strong financial performance with significant growth in cloud revenues and […]
Cipher Pharma – Potential Multibagger in Toenail Fungus – CPH.TOCipher Pharmaceuticals – CPH.TO
Pitch Summary: Cipher Pharmaceuticals has seen its stock rise significantly due to the potential of MOB-015, a topical treatment for toenail fungus, which could disrupt the Canadian market dominated by less effective treatments. The Canadian market for onychomycosis is largely untapped, with only 20% of sufferers currently seeking treatment. MOB-015 has shown superior efficacy in […]
Moberg Pharma – Toenail Fungus Pure-Play with Potential- MOB.STMoberg Pharma – MOB.ST
Pitch Summary: Moberg Pharma’s MOB-015, branded as Terclara, is positioned to be a superior treatment for toenail fungus compared to existing topical and oral treatments. While oral terbinafine has a higher complete cure rate, it comes with significant side effects, making MOB-015 a safer alternative. The ongoing phase three trial aims to improve the complete […]
Moberg & Cipher – The Final Puzzle Pieces – $MOB.ST $CPH.TOCipher Pharmaceuticals – CPH.TO
Pitch Summary: Cipher Pharmaceuticals holds the Canadian distribution rights for MOB-015, a promising topical treatment for toenail fungus developed by Moberg Pharma. The treatment’s ability to achieve high mycological cure rates with a safer profile than oral alternatives positions it well for market success. The ongoing phase three trial aims to optimize the treatment regimen […]
